Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dextrose provides a source of calories and is metabolized to carbon dioxide and water, producing energy. Sodium chloride maintains electrolyte balance and osmotic pressure. Potassium chloride replaces potassium for cellular ion exchange and acid-base balance.
Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.
Intravenous infusion for fluid and electrolyte replacement,Treatment of hypokalemia,Treatment of dehydration with electrolyte imbalance,Maintenance of hydration and electrolyte balance when oral intake is inadequate
Treatment of herpes simplex virus (HSV) infections (genital herpes, herpes labialis, herpes simplex encephalitis),Treatment of varicella-zoster virus (VZV) infections (chickenpox, herpes zoster),Neonatal herpes simplex virus infection,Off-label: Prevention of HSV reactivation in immunocompromised patients, treatment of eczema herpeticum
Intravenous infusion. Dosing is individualized based on fluid, electrolyte, and caloric requirements. Typical adult maintenance dose: 1-3 L/day at a rate of 50-125 m L/hour. Maximum infusion rate: 0.5 g/kg/hour for glucose; potassium infusion rate should not exceed 10 m Eq/hour or 200 m Eq/day in adults.
5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.
Dextrose: ~15-20 min (rapid uptake into cells). Potassium: ~8-12 h (redistribution half-life ~1 h; terminal elimination depends on renal function, clinical context: prolonged in renal impairment).
Terminal elimination half-life in adults with normal renal function is 2.5-3.3 hours. In anuric patients, half-life extends to approximately 19.5 hours, necessitating dosage adjustment in renal impairment.
Dextrose undergoes glycolysis and subsequent metabolism to carbon dioxide and water. Sodium chloride is excreted renally. Potassium is primarily excreted by the kidneys.
Acyclovir is partially metabolized by aldehyde oxidase and alcohol dehydrogenase to 9-carboxymethoxymethylguanine and other minor metabolites. The majority (62-90%) is excreted unchanged in urine via glomerular filtration and tubular secretion.
Renal: >95% of dextrose (as CO2 via respiration) and sodium and chloride (with water); potassium excreted renally, ~90% reabsorbed, distal secretion under aldosterone control. Minimal fecal/biliary.
Primarily renal excretion via glomerular filtration and tubular secretion; approximately 62-91% of an administered dose is recovered unchanged in urine. Fecal excretion is minimal (<2%).
Dextrose: <10% (not significantly bound). Potassium: minimal (<5%). Sodium and chloride: negligible.
9-33% bound to plasma proteins; binding is concentration-independent and predominantly to albumin.
Dextrose: ~0.2 L/kg (total body water). Sodium: ~0.6 L/kg. Chloride: ~0.3 L/kg. Potassium: ~0.4-0.5 L/kg (primarily intracellular, >98% in cells). Clinical meaning: reflects distribution into extracellular and intracellular compartments.
Approximately 0.7 L/kg, indicating distribution into total body water. Penetrates well into tissues, including cerebrospinal fluid (CSF concentrations ~50% of plasma).
IV: 100% (complete bioavailability for all components). Not administered orally for this specific product.
Intravenous administration yields 100% bioavailability. Oral bioavailability is 15-30% (not applicable to IV formulation).
GFR > 50 m L/min: no adjustment. GFR 10-50 m L/min: dose potassium cautiously, monitor serum potassium. GFR < 10 m L/min: avoid potassium chloride unless hypokalemia is severe and monitored closely; may require reduced volume and potassium content.
Cr Cl >50 m L/min: no adjustment; Cr Cl 25-50 m L/min: 5-10 mg/kg every 12 hours; Cr Cl 10-25 m L/min: 5-10 mg/kg every 24 hours; Cr Cl <10 m L/min: 2.5-5 mg/kg every 24 hours; hemodialysis: give dose after dialysis.
Child-Pugh A: no adjustment. Child-Pugh B: monitor potassium and glucose. Child-Pugh C: use with caution, adjust potassium based on serum levels; may require reduced infusion rate due to risk of glucose intolerance.
No dose adjustment required for hepatic impairment; acyclovir is minimally metabolized by the liver.
Weight-based dosing: 100-200 m L/kg/day for maintenance fluids, adjusted for deficits and ongoing losses. Potassium concentration: typically 20 m Eq/L, infused at a rate not exceeding 0.5-1 m Eq/kg/hour. Glucose infusion rate: start at 4-8 mg/kg/min, titrate to serum glucose.
Neonates (0-3 months): 10 mg/kg IV every 8 hours for HSV; Infants and children (3 months-12 years): 10 mg/kg IV every 8 hours for HSV, 20 mg/kg IV every 8 hours for VZV; maximum dose 500 mg/m² per dose.
Start at lower end of adult dose; monitor renal function and serum electrolytes closely. Reduce infusion rate if renal impairment present; avoid overhydration. Potassium supplementation should be cautious due to age-related decline in renal function.
Elderly patients may have reduced renal function; adjust dose based on Cr Cl and monitor for neurotoxicity (e.g., confusion, hallucinations).
Potassium chloride injection concentrate must be diluted before use to avoid fatal hyperkalemia.
None.
Risk of hyperkalemia if potassium is not properly administered or in renal impairment,Risk of fluid overload in patients with cardiac or renal disease,Monitor serum electrolytes, blood glucose, and renal function,Use with caution in patients with diabetes mellitus or impaired glucose tolerance
Renal impairment: Dose adjustment required; monitor renal function.,Neurotoxicity: May cause agitation, hallucinations, confusion, seizures (especially in elderly or renally impaired).,Crystalluria: Risk increased with rapid infusion or dehydration; ensure adequate hydration.,Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP): Rare but serious, reported in immunocompromised patients.,Pregnancy: Use only if clearly needed (Category B).
Hyperkalemia (serum potassium >5.5 m Eq/L),Severe renal impairment with oliguria or anuria,Hypernatremia,Cardiac decompensation or severe congestive heart failure,Known hypersensitivity to any component
Hypersensitivity to acyclovir, valacyclovir, or any component of the formulation.,Neonates: Use of bacteriostatic water-containing preparations (e.g., benzyl alcohol) is contraindicated.
Avoid potassium-rich foods (e.g., bananas, oranges, potatoes, tomatoes, salt substitutes) unless directed by your doctor, to prevent hyperkalemia. Maintain normal dietary intake of sodium and fluids as instructed.
No specific food interactions. Adequate fluid intake is recommended to prevent renal toxicity. Avoid concurrent use of nephrotoxic substances (e.g., certain NSAIDs, aminoglycosides) without medical supervision.
Dextrose, sodium chloride, and potassium chloride are essential nutrients and electrolytes; no teratogenic risk is expected at physiological levels. However, rapid correction of maternal electrolyte imbalances or hyperglycemia may cause fetal distress. First trimester: No known teratogenicity. Second and third trimesters: Risk is related to maternal metabolic derangements rather than direct drug effects.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; use only if clearly needed.
Dextrose, sodium, and potassium are normal constituents of breast milk. Supplementation in the mother does not significantly alter breast milk levels. No known adverse effects in breastfeeding infants. No M/P ratio available.
Acyclovir excreted in breast milk at low levels; M/P ratio unknown. Typical infant dose ~0.6 mg/kg/day (2-3% of maternal IV dose). No adverse effects reported in breastfeeding infants. Compatible with breastfeeding; caution with high maternal doses.
Pregnancy may increase fluid requirements and alter electrolyte balance; adjust infusion rates based on maternal clinical status and laboratory values. No standard dose reduction; use clinical judgment to avoid volume overload or electrolyte imbalances.
Increased renal clearance and volume of distribution in pregnancy may reduce acyclovir exposure. No dose adjustment routinely recommended; however, higher doses or more frequent dosing may be considered for severe infections. Monitor therapeutic response.
This solution provides maintenance fluid with dextrose to prevent ketosis and potassium to prevent hypokalemia. Monitor serum potassium and renal function; stop infusion if urine output <0.5 m L/kg/h for 2 consecutive hours. Use with caution in patients with heart failure, renal impairment, or hyperkalemia. Do not administer rapidly; maximum infusion rate 0.5 m Eq/kg/h potassium.
Acyclovir in sodium chloride 0.9% preservative-free is for IV administration only; do not administer IM or SC. Infuse over at least 1 hour to prevent renal tubular damage. Monitor renal function and adjust dose in renal impairment (Cr Cl <50 m L/min). Ensure adequate hydration (e.g., 500 m L IV fluids per gram acyclovir) to reduce risk of crystalluria. In obese patients, use ideal body weight for dosing. Phlebitis at infusion site is common; rotate sites.
Report any chest pain, shortness of breath, or swelling in your legs or ankles.,Tell your doctor if you feel muscle weakness, tingling, or irregular heartbeat.,This fluid contains sugar; if you have diabetes, your blood sugar may increase.,Do not suddenly stop the infusion; it should be tapered if discontinuing.,Keep your appointment for blood tests to monitor potassium and kidney function.
This medication is given intravenously (into a vein) to treat viral infections.,Drink plenty of fluids before and during treatment to prevent kidney problems.,Report any pain, redness, or swelling at the injection site, or any lower back pain.,Tell your healthcare provider if you have kidney disease or are taking other medications that can affect the kidneys.,This drug does not cure herpes infections but helps reduce symptoms and recurrence.
"Atracurium besylate, a nondepolarizing neuromuscular blocking agent, may enhance the ulcerogenic potential of oral potassium chloride by reducing gastrointestinal motility and increasing local contact time of the potassium chloride tablet with the gastric and intestinal mucosa. This prolonged exposure can heighten the risk of gastrointestinal erosion, bleeding, or perforation, particularly in patients with pre-existing lesions or receiving high-dose potassium supplementation. Clinically, this interaction necessitates close monitoring for signs of gastrointestinal injury when these agents are coadministered."
"Methscopolamine bromide, an anticholinergic agent, reduces gastrointestinal motility and delays gastric emptying, which can prolong the contact time of orally administered Potassium chloride (KCl) tablets or capsules with the gastric mucosa. This increased exposure to high concentrations of potassium in the gastrointestinal tract potentiates the local ulcerogenic effect of KCl, leading to a higher risk of esophageal, gastric, or intestinal erosions, ulcers, hemorrhage, perforation, or stricture formation. Clinically, this interaction may present with dysphagia, epigastric pain, hematemesis, melena, or signs of acute abdomen."
"Fesoterodine, an anticholinergic agent used for overactive bladder, can reduce gastric motility and prolong gastrointestinal transit time. This effect may increase the local contact time of potassium chloride tablets with the gastrointestinal mucosa, potentiating the ulcerogenic risk of potassium chloride, which can cause esophageal or intestinal ulceration, stenosis, or perforation. The interaction is clinically significant in patients with pre-existing gastrointestinal motility disorders or those taking high-dose potassium supplements."
"Teriflunomide, the active metabolite of leflunomide, inhibits dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine synthesis, exerting immunomodulatory effects. Acyclovir, an antiviral nucleoside analog, may inhibit organic anion transporter 3 (OAT3)-mediated renal tubular secretion of teriflunomide, leading to increased systemic exposure. Elevated teriflunomide concentrations can potentiate hepatotoxicity, myelosuppression, and immunosuppression, increasing the risk of infections and other adverse effects."
"The serum concentration of Acyclovir can be increased when it is combined with Tizanidine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, answered by our medical review team.
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER is a Electrolyte that works by Dextrose provides a source of calories and is metabolized to carbon dioxide and water, producing energy. Sodium chloride maintains electrolyte balance and osmotic pressure. Potassium chloride replaces potassium for cellular ion exchange and acid-base balance.. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is a Electrolyte that works by Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER is: Intravenous infusion. Dosing is individualized based on fluid, electrolyte, and caloric requirements. Typical adult maintenance dose: 1-3 L/day at a rate of 50-125 m L/hour. Maximum infusion rate: 0.5 g/kg/hour for glucose; potassium infusion rate should not exceed 10 m Eq/hour or 200 m Eq/day in adults.. The standard adult dose of ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is: 5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER is classified as Category A/B. Dextrose, sodium chloride, and potassium chloride are essential nutrients and electrolytes; no teratogenic risk is expected at physiological levels. However, rapid correction of ma. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is classified as Category A/B. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; us. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.